Strong Large Pharma Growth
Revenue from large pharma customers increased in low double digits, reflecting continued demand for Bio-Techne's tools and technologies.
China Market Growth
China delivered its second consecutive quarter of growth, supported by improving CRO pipelines and increased CDMO activity.
Adjusted Operating Margin Expansion
Adjusted operating margin expanded by 90 basis points year-over-year to 29.9%, exceeding initial expectations.
ProteinSimple Instrument Momentum
The ProteinSimple instrument franchise showed strong utilization, with double-digit growth in cartridge consumable pull-through.
Sustainability Achievements
Bio-Techne achieved an estimated 40% reduction in Scope 1 and 2 emissions by transitioning to 100% renewable electricity at its largest site.